Haleon - HLN Enterprise Value-to-Revenue Multiple

Official company branding of Haleon (HLN)

Haleon plc relies on years of brand trust, which creates a stable cash flow. The company's products address the fundamental hygiene and health needs of billions of people. The EV/Sales ratio confirms this resilience, with the current level standing at 3317.64. However, business success is based on demand seasonality, raw material prices, and customer loyalty.

haleon.com (HLN): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

HLN (Haleon): analytical breakdowns and indicator data

- share price and expert price forecast:
Initial company analysis:Haleon plc - HLN
Product sample of haleon.com

The current enterprise value-to-revenue valuation confirms the status of Haleon plc (HLN) as a defensive asset within the consumer health sector. This metric compares the total business value to annual turnover, excluding the impact of leverage to identify the actual market premium. Given the steady demand for over-the-counter medications, the low volatility of this ratio signals the fundamental strength of the issuer's position.

Competitor analysis for Haleon plc

Enterprise Value-to-Revenue Multiple kenvue.com|Verona Pharma (VRNA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Jyong Biotech Limited (MENS)|LGND (Ligand Pharmaceuticals Incorporated) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amneal Pharmaceuticals Inc AMRX|EV/Sales Multiple PRGO|Enterprise Value-to-Revenue Coefficient ALVO|EV/Sales Multiple LQDA (Liquidia Technologies)|EV/Sales Multiple Galapagos GLPG|ANI Pharmaceuticals Inc - EV/Sales Multiple|MNKD (MannKind Corp.) - Company Value to Revenue Ratio|AMPH: EV/Sales Multiple|PCRX (Pacira BioSciences) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ARS Pharmaceuticals Inc|Company Value to Revenue Theravance Biopharma, Inc. (TBPH)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio